BEAM Beam Therapeutics Inc.
$23.79▼ -0.02%
Healthcare
Other
Volume 92.9K
Avg Volume (10D) 1.51M
Key Metrics & Fundamentals
Market Cap
$2.46B
P/E Ratio
–
Div Yield
0.00%
52W Range
20.23 - 38.26
% vs 50 MA
-8.35%
% vs 200 MA
-15.78%
RSI-14
43.2
MACD Histogram
+0.0300
Beta (1Y vs SPY)
2.10
Free Cash Flow
-$68.51M
Gross Rev
$490,000
Gross Profit
$490,000
EBITDA
-$117.08M
COGS
–
Operating Exp
$127.04M
Operating Income
-$126.55M
EBIT
-$126.55M
Pretax Income
-$123.13M
Net Income
-$122.68M
EPS (Diluted)
-1.18
Price & Volume History
Loading chart…
Recent News
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
GlobeNewswire · Oct 27, 2026 7:00 AM ET
Beam Therapeutics Insider Sold Shares Worth $1,188,745, According to a Recent SEC Filing
MT Newswires · Oct 19, 2026 4:07 AM ET
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
Motley Fool · Oct 17, 2026 9:20 PM ET
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress
GlobeNewswire · Oct 13, 2026 7:00 AM ET
Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative
Simply Wall St. · Sep 30, 2026 9:23 PM ET
Beam sues 2 biotechs, alleging theft of base editing trade secrets
BioPharma Dive · Sep 29, 2026 2:34 PM ET
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Barchart · Sep 29, 2026 9:00 AM ET
As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock
Barchart · Sep 28, 2026 5:02 PM ET
Cathie Wood Makes $64 Million Bet on Two Stocks
GuruFocus.com · Sep 28, 2026 3:11 PM ET
Anthropic AI Discovery Gene-Editing Stocks Falling
GuruFocus.com · Sep 24, 2026 8:46 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See BEAM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.